Blueprint Medicines (NASDAQ:BPMC) Stock Price Down 1.6% – Time to Sell?

Blueprint Medicines Co. (NASDAQ:BPMC)’s stock price traded down 1.6% on Friday . The stock traded as low as $88.20 and last traded at $88.37. 55,876 shares changed hands during mid-day trading, a decline of 94% from the average session volume of 1,000,307 shares. The stock had previously closed at $89.84.

Analyst Ratings Changes

A number of analysts recently issued reports on BPMC shares. Wedbush reissued an “outperform” rating and set a $128.00 price target on shares of Blueprint Medicines in a report on Friday, February 28th. Stephens restated an “overweight” rating and issued a $140.00 price objective on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Needham & Company LLC reiterated a “buy” rating and set a $133.00 target price on shares of Blueprint Medicines in a research report on Thursday, February 13th. Guggenheim reissued a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, February 14th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $125.21.

Blueprint Medicines Stock Down 0.3 %

The business’s 50 day moving average price is $99.46 and its 200-day moving average price is $94.09. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. The firm has a market capitalization of $5.72 billion, a PE ratio of -82.84 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. As a group, equities research analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Insider Activity

In other news, Director Jeffrey W. Albers sold 15,000 shares of the firm’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $89.77, for a total value of $1,346,550.00. Following the completion of the sale, the director now owns 157,557 shares in the company, valued at approximately $14,143,891.89. This trade represents a 8.69 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ariel Hurley sold 3,203 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total value of $296,661.86. Following the completion of the transaction, the insider now directly owns 18,270 shares of the company’s stock, valued at $1,692,167.40. The trade was a 14.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 46,608 shares of company stock valued at $4,668,161 in the last ninety days. 4.21% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Blueprint Medicines

Several hedge funds and other institutional investors have recently made changes to their positions in BPMC. Empirical Asset Management LLC acquired a new position in shares of Blueprint Medicines in the 4th quarter valued at about $2,348,000. Stephens Inc. AR purchased a new stake in shares of Blueprint Medicines in the 4th quarter valued at approximately $321,000. Massachusetts Financial Services Co. MA lifted its stake in Blueprint Medicines by 48.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company’s stock worth $23,332,000 after acquiring an additional 82,693 shares in the last quarter. Entropy Technologies LP acquired a new stake in shares of Blueprint Medicines during the 3rd quarter valued at $999,000. Finally, KBC Group NV grew its stake in shares of Blueprint Medicines by 63.9% in the 4th quarter. KBC Group NV now owns 2,625 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 1,023 shares in the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.